J Pharm Pharmacogn Res 2(Suppl. 1): S20, 2014
Special supplement with the abstract book of LATINFARMA 2013
CO 038: FREQUENCY OF USE OF THE MONOCLONAL ANTIBODY RITUXIMAB ON THE NATIONAL CANCER INSTITUTE OF MEXICO: ONE YEAR EXPERIENCE
López-Gamboa M1,2, Aguilar-Ponce JL2, Espinoza-Zamora JR2, DavalosFiesco M2, Mena-Rodríguez FJ2, Castañeda-Hernández G1.
Introduction: For the health care professionals and for the maker decisions staff on the hospital is very important have a real panorama about the use of the drugs in order to improve the patient attention. In Mexico for the oncology therapeutic segment, Rituximab the chimeric, anti-CD20 monoclonal antibody is registered for: a) the treatment of Non-Hodgking´s Lymphoma (CD20+); b) also combined with chemotherapy for previously untreated patients with relapsed/refractory of chronic lymphocytic leukemia.
Methods: With the aim of determine the Rituximab frequency usage on the National Cancer Institute of Mexico we made a retrospective analysis of the rituximab dispensation data from march 2012 to march 2013. Our collected data were: the pharmaceutical presentation and vials quantity of Rituximab dispensed per patient; and from the clinical record the data recorded included: clinical indication (diagnostic) result of CD20 test, weigh, height, age, and Rituximab dosage prescribed.
Results: During the twelve-month period, a total of 2663 Rituximab vials where dispensed from the Institute pharmacy, 1353 were 500 mg vials, and 1308 were 100 mg vials, distributed on 304 patients. The list of primary diagnostics included 75 different pathologies. All patients had immunohystochemical test, the 95% of the cases were positive to the CD 20 test, 4.7% of the patients had not report and 0.3% were negative to the CD20 test.
Conclusion: Even when Rituximab was prescribed for a diverse range of clinical conditions, the use of CD20 test was a standard followed on the patients, this practice showed the specific use of Rituximab.